Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development Apr 1, 2024 08:00AM
Synlogic (SYBX) Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria Feb 2, 2024 12:00PM
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria Feb 2, 2024 12:00PM
Synlogic (SYBX) Provides Corporate Update and Outlook for 2024 Jan 4, 2024 07:06AM
Synlogic Provides Corporate Update and Outlook for 2024 Jan 4, 2024 07:00AM


Dec 27, 2023 07:03AM Synlogic (SYBX) Announces Contract with the Air Force Research Lab
Dec 27, 2023 07:00AM Synlogic Announces Contract with the Air Force Research Lab
Dec 7, 2023 07:00AM Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
Nov 9, 2023 07:00AM Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 7, 2023 07:03AM Synlogic (SYBX) Achieves Research Milestone, Earns $2.5M Milestone Payment
Nov 7, 2023 07:00AM Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
Oct 3, 2023 04:15PM Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
Sep 29, 2023 07:00AM Synlogic (SYBX) Prices 7.39M Share Offering at $2.84/sh
Sep 29, 2023 07:00AM Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
Sep 28, 2023 11:16AM Synlogic (SYBX) Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
Sep 28, 2023 11:15AM Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
Sep 27, 2023 12:30PM Synlogic (SYBX) Announces Reverse Stock Split
Sep 27, 2023 12:30PM Synlogic Announces Reverse Stock Split
Sep 21, 2023 07:00AM Synlogic to Participate in Chardan’s Genetic Medicines Conference
Sep 19, 2023 11:00AM Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
Aug 10, 2023 07:00AM Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
Jul 11, 2023 07:00AM Synlogic (SYBX) Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
Jul 11, 2023 07:00AM Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
Jun 28, 2023 07:00AM Synlogic Announces International Nonproprietary Name Selection for SYNB1934
Jun 27, 2023 07:00AM Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
Jun 8, 2023 06:45AM Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
Jun 5, 2023 06:45AM Synlogic (SYBX) Initiates Phase 3 Study of SYNB1934
Jun 5, 2023 06:45AM Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
Aug 25, 2017 10:00AM Synlogic (Nasdaq: SYBX) to Ring The Nasdaq Stock Market Closing Bell